Heart failure (HF) has become a subject of continuous interest since it was declared a new
pandemic in 1997 because of the exponential increase in hospitalizations for HF in the latest …

Heart failure with preserved ejection fraction (HFpEF) results from a complex interplay of
age, genetic, cardiac remodeling, and concomitant comorbidities including hypertension …

Heart failure (HF) is a clinical syndrome due to either functional or structural impairment of
the ventricular pump or filling, representing a major cause of global morbidity and mortality …

Introduction Ejection fraction (EF) is widely used to evaluate heart function during heart
failure (HF) due to its simplicity compared but it may misrepresent cardiac function during …

Heart failure (HF) is a debilitating clinical syndrome affecting 64.3 million patients worldwide.
More than 50% of HF cases are attributed to HF with preserved ejection fraction (HFpEF), an …

Background Myocardial contraction fraction (MCF)—the ratio of left ventricular stroke volume
to myocardial volume—is a volumetric measure of myocardial shortening that distinguishes …

Heart failure with preserved ejection fraction presents a major clinical challenge due to its
complex pathophysiology and limitations in its therapeutic options. This comprehensive …

Heart failure (HF) can be divided into HF with reduced or preserved ejection fraction (HFrEF
or HFpEF). Research into the treatment of HF has focused on HFrEF for decades, while …

Chen et al. used a rat model of cardiopulmonary bypass followed by 30-min ischemia
(induced by ascending aorta blockage) and 15-min reperfusion [1]. They reported that …

The management of heart failure (HF) in patients with type 2 diabetes has significantly
evolved with the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors. This …